Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | AKT1 | P31749 | 3/20 | 0.44 |
| ▸ | CTSS | P25774 | 5/20 | 0.43 |
| ▸ | CTSL | P07711 | 3/20 | 0.43 |
| ▸ | CTSB | P07858 | 3/20 | 0.43 |
| ▸ | CTSK | P43235 | 3/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1020978 | 0.94 | MEN1 (0.46) | SYKIDO1AKT1CTSSCTSL | |
| SCHEMBL1022568 | 0.89 | CTSS (0.47) | SYKIDO1AKT1CTSSCTSL | |
| SCHEMBL1021954 | 0.88 | SYK (0.51) | SYKMEN1KMT2AGAA | |
| SCHEMBL1020939 | 0.83 | MEN1 (0.51) | SYKIDO1AKT1CTSSCTSL | |
| SCHEMBL4850221 | 0.81 | SYK (0.49) | SYKIDO1AKT1CTSSCTSL | |
| SCHEMBL4850228 | 0.81 | SYK (0.49) | SYKIDO1AKT1CTSSCTSL | |
| SCHEMBL1022823 | 0.81 | AKT1 (0.48) | SYKIDO1AKT1CTSSCTSL | |
| SCHEMBL1024146 | 0.81 | AKT1 (0.48) | SYKIDO1AKT1CTSSCTSL | |
| SCHEMBL1022884 | 0.81 | CTSK (0.53) | AKT1CTSSCTSLCTSBCTSK | |
| SCHEMBL4856502 | 0.80 | SYK (0.48) | SYKIDO1AKT1CTSSCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1797110-B1 | ANTIBACTERIAL AMIDE MACROCYCLES IV | AICURIS GMBH & CO KG (DE) | 2011-01-12 | — | — | EP | disclosed |
| US-7446102-B2 | Antibacterial amide macrocycles IV | AICURIS GMBH & CO. KG (DE) | 2008-11-04 | — | — | US | disclosed |
| US-20080076745-A1 | ANTIBACTERIAL AMIDE MACROCYCLES IV | AICURIS GMBH & CO. KG (DE) | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076745-A1 | ANTIBACTERIAL AMIDE MACROCYCLES IV | NOD2, AAAS, AADAC | SYK 3060/4885IDO1 2481/4885AKT1 4247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.